164 related articles for article (PubMed ID: 8380661)
1. Attachment of neutralizing antibodies stabilizes the capsid of poliovirus against uncoating.
Wetz K
Virology; 1993 Feb; 192(2):465-72. PubMed ID: 8380661
[TBL] [Abstract][Full Text] [Related]
2. Antigenicity and immunogenicity of poliovirus capsid proteins.
van Wezel AL; van der Marel P; Hazendonk TG; Boer-Bak V; Henneke MA
Dev Biol Stand; 1983; 55():209-15. PubMed ID: 6203795
[TBL] [Abstract][Full Text] [Related]
3. Docking of a human rhinovirus neutralizing antibody onto the viral capsid.
Tormo J; Centeno NB; Fontana E; Bubendorfer T; Fita I; Blaas D
Proteins; 1995 Dec; 23(4):491-501. PubMed ID: 8749845
[TBL] [Abstract][Full Text] [Related]
4. Induction of neutralizing antibodies by type 1 poliovirus VP1 capsid polypeptide.
Crainic R; Blondel B; Horaud F
Dev Biol Stand; 1983; 55():185-9. PubMed ID: 6329856
[TBL] [Abstract][Full Text] [Related]
5. Antigenic analysis of poliovirus type 3 using monoclonal antibodies.
Ferguson M; Minor PD; Magrath DI; Schild GC
Dev Biol Stand; 1984; 57():151-5. PubMed ID: 6098495
[TBL] [Abstract][Full Text] [Related]
6. Immunochemical studies of polioviruses: identification of immunoreactive virus capsid polypeptides.
Thorpe R; Minor PD; Mackay A; Schild GC; Spitz M
J Gen Virol; 1982 Dec; 63(2):487-92. PubMed ID: 6185628
[TBL] [Abstract][Full Text] [Related]
7. Poliovirus neutralization by antibodies to internal epitopes of VP4 and VP1 results from reversible exposure of these sequences at physiological temperature.
Li Q; Yafal AG; Lee YM; Hogle J; Chow M
J Virol; 1994 Jun; 68(6):3965-70. PubMed ID: 7514682
[TBL] [Abstract][Full Text] [Related]
8. Monospecific antisera against capsid polypeptides of poliovirus type 1 distinguish antigenic structures of poliovirus proteins.
Wiegers KJ; Dernick R
J Gen Virol; 1983 Apr; 64 (Pt 4)():777-85. PubMed ID: 6300300
[TBL] [Abstract][Full Text] [Related]
9. Neutralization epitopes on poliovirus type 3 particles: an analysis using monoclonal antibodies.
Ferguson M; Minor PD; Magrath DI; Qui YH; Spitz M; Schild GC
J Gen Virol; 1984 Jan; 65 ( Pt 1)():197-201. PubMed ID: 6198447
[TBL] [Abstract][Full Text] [Related]
10. Ability of linear and cyclic peptides of neutralization antigenic site 1 of poliovirus type 1 to induce virus cross-reactive and neutralizing antibodies.
van der Werf S; Briand JP; Plaué S; Burckard J; Girard M; Van Regenmortel MH
Res Virol; 1994; 145(6):349-59. PubMed ID: 7535942
[TBL] [Abstract][Full Text] [Related]
11. A technique to detect the reaction between poliovirus structural polypeptides and neutralizing anti-polio IgG.
Blondel B; Crainic R
Dev Biol Stand; 1981; 47():335-7. PubMed ID: 6262158
[TBL] [Abstract][Full Text] [Related]
12. Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template.
Cello J; Paul AV; Wimmer E
Science; 2002 Aug; 297(5583):1016-8. PubMed ID: 12114528
[TBL] [Abstract][Full Text] [Related]
13. Neutralization of poliovirus by polyclonal antibodies requires binding of a single IgG molecule per virion.
Wetz K; Willingmann P; Zeichhardt H; Habermehl KO
Arch Virol; 1986; 91(3-4):207-20. PubMed ID: 3022677
[TBL] [Abstract][Full Text] [Related]
14. Analysis of specificity of antibodies contained in antiserum against poliovirus with mutants resistant to inhibitors in equine serum.
Urasawa S; Urasawa T; Kanamitsu M
J Immunol; 1974 Aug; 113(2):537-42. PubMed ID: 4367633
[No Abstract] [Full Text] [Related]
15. Antigenic sites of poliovirus type 3 eliciting IgA monoclonal antibodies in orally immunized mice.
Buttinelli G; Ruggeri FM; Marturano J; Novello F; Donati V; Fiore L
Virology; 2001 Mar; 281(2):265-71. PubMed ID: 11277698
[TBL] [Abstract][Full Text] [Related]
16. Disoxaril stabilization and immunogenicity of poliovirus procapsids.
Rombaut B; Brioen P; Boeyé A
J Gen Virol; 1990 May; 71 ( Pt 5)():1081-6. PubMed ID: 2161045
[TBL] [Abstract][Full Text] [Related]
17. Induction of neutralizing antibodies by poliovirus capsid polypeptides VP1, VP2 and VP3.
van der Marel P; Hazendonk TG; Henneke MA; van Wezel AL
Vaccine; 1983 Dec; 1(1):17-22. PubMed ID: 6099638
[TBL] [Abstract][Full Text] [Related]
18. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate.
Mayr GA; Chinsangaram J; Grubman MJ
Virology; 1999 Oct; 263(2):496-506. PubMed ID: 10544121
[TBL] [Abstract][Full Text] [Related]
19. Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region.
Burns CC; Shaw J; Campagnoli R; Jorba J; Vincent A; Quay J; Kew O
J Virol; 2006 Apr; 80(7):3259-72. PubMed ID: 16537593
[TBL] [Abstract][Full Text] [Related]
20. Canyon rim residues, including antigenic determinants, modulate serotype-specific binding of polioviruses to mutants of the poliovirus receptor.
Harber J; Bernhardt G; Lu HH; Sgro JY; Wimmer E
Virology; 1995 Dec; 214(2):559-70. PubMed ID: 8553558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
